ClinicalTrials.gg
Sign In
Status unknownNCT06500351Updated Jul 16, 2024

Renalase(rs10887800) Genotyping & Leucocytes Telomere Length in Postpartum. Hypertension

An observational study in Renalase(rs10887800) Genotyping & Leucocytes Telomere Length in Patients With Postpartum Hypertension, sponsored by Sohag University. Status unknown at 1 site in Egypt. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-07-16.

Sponsored by Sohag University · Observational

The sponsor has not verified this record recently (last verified Jul 2024), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
90
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

This is an observertional study aimed at Study the association between Renalase(rs10887800) Genotyping \& Leucocytes telomere length in patients with postpartum hypertension whether new onset( denovo) or persistent following pregnancy complicated by hypertension.

02

Conditions studied

  • Renalase(rs10887800) Genotyping & Leucocytes Telomere Length in Patients With Postpartum Hypertension
03

In context

Lead sponsor

Sohag University is the lead sponsor of 1,220 studies on the registry; 629 are open to participants now.

Browse Sohag University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Sampling method
Probability sample

Study population

Patients who were 18 years or above, and have a diagnosis of postpartum hypertension

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are18 years or above, and have a diagnosis of postpartum hypertension(regardless of where they received their antenatal care) attended to Sohag university hospitals

Exclusion criteria

Exclusion Criteria:

  • All pregnant women with medical disorders in pregnancy other than Hypertensive disorders during pregnancy (e.g., sickle cell disease, heart disease, kidney and other connective tissues disorders) will be excluded from the study. Also we excluded measurements taken during scheduled or unscheduled surgical encounters given potential for interaction with anesthetic agents
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • denovo postpartum hypertension

    females with new onset hypertension after delivary

  • persitant postpartum hypertension

    females with preexisting hypertension or preeclampsia that persist after delivery

  • control

    females with normal postpartum blood pressure

06

What researchers measure

Primary outcomes

  1. Renalase(rs10887800) Genotyping

    The presence of gene polymorphism whether homogenetic or heterogenetic

    Time frame: 1 year

Secondary outcomes

  1. Leucocytes telomere length

    Measurement of the relative length of WBCs telomere in patints with postpartum hypertension

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Sohag university hosoital
    Sohag, Egypt
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Jun 2025, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2024
First posted
Jul 15, 2024
StartActual
Jun 25, 2024
Primary completionEst.
Jun 25, 2025
CompletionEst.
Sep 1, 2025
Last update
Jul 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06500351
Lead sponsor
Sohag University
Responsible party
Amera Morad Foad (Assistant Professor of Medical Biochemistry, Sohag University) — Principal investigator
First posted
Jul 15, 2024
Start date
Jun 25, 2024
Primary completion
Jun 25, 2025 (estimated)
Completion
Sep 1, 2025 (estimated)
Last update
Jul 16, 2024

Study contacts

Amera Morad Foad, assistant professor
Contact
ameramoradfoad@gmail.com
+201006591449
Amera Morad Foad, assistant professor
principal investigator · Sohag University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Sohag University →

Start the discussion